AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said AbbVie Inc. ABBV is a very strong health care provider.

On July 25, AbbVie reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57. Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.

Stephen Weiss of Short Hills Capital Partners said Leidos Holdings, Inc. LDOS reported stable earnings.

On July 30, Leidos reported better-than-expected second-quarter fiscal 2024 earnings. The company posted revenue growth of 8% year-over-year to $4.13 billion, beating the analyst consensus estimate of $4.06 billion, driven by demand across all customer segments, especially for managed health services.

Don't forget to check out our premarket coverage here

Stephanie Link of Hightower named iShares U.S. Healthcare ETF IYH as her final trade.

Joseph M. Terranova of Virtus Investment Partners picked KKR & Co. Inc. KKR.

On July 31, KKR & Co posted second-quarter earnings of 72 cents per share on sales of $4.17 billion. On Aug. 2, Citigroup analyst Chris Allen maintained KKR with a Buy rating, while raising the price target from $130 to $150.

Price Action:

• AbbVie shares fell 2.6% to close at $184.36 on Monday.
• Leidos gained 0.9% during Friday's session.
• iShares U.S. Healthcare ETF fell 2.6% during Monday's session.
• KKR shares fell 2.2% to settle at $106.23 on Monday.

Check This Out:

• Top 3 Tech Stocks That Could Surge This Quarter

Image created using artificial intelligence via Midjourney.